Clinical implementation of integrated molecular‐morphologic risk prediction for meningioma
Brain Pathology · 2023-05 · 33 (3)
DOI: 10.1111/bpa.13132 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain Pathology, online erschienen am 14.11.2022. Verfasst von Thomas Hielscher und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany. Hauptthemen laut MEDLINE: Meningioma, Meningeal Neoplasms. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Medical Research Council, Deutsche Krebshilfe, Gemeinnützige Hertie‐Stiftung.
Abstract (Originalsprache)
Risk prediction for meningioma tumors was until recently almost exclusively based on morphological features of the tumor. To improve risk prediction, multiple models have been established that incorporate morphological and molecular features for an integrated risk prediction score. One such model is the integrated molecular‐morphologic meningioma integrated score (IntS), which allocates points to the histological grade, epigenetic methylation family and specific copy‐number variations. After publication of the IntS, questions arose in the neuropathological community about the practical and clinical implementation of the IntS, specifically regarding the calling of CNVs, the applicability of the newly available version (v12.5) of the brain tumor classifier and the need for incorporation of TERT ‐promoter and CDKN2A/B status analysis in the IntS calculation. To investigate and validate these questions additional analyses of the discovery ( n = 514), retrospective validation ( n = 184) and prospective validation ( n = 287) cohorts used for IntS discovery and validation were performed. Our findings suggest that any loss over 5% of the chromosomal arm suffices for the calling of a CNV, that input from the v12.5 classifier is as good or better than the dedicated meningioma classifier (v2.4) and that there is most likely no need for additional testing for TERT ‐promoter mutations and/or homozygous losses of CDKN2A/B when defining the IntS for an individual patient. The findings from this study help facilitate the clinical implementation of IntS‐based risk prediction for meningioma patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
- Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
- Department of Neuropathology, University Hospital Heidelberg and CCU Neuropathology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
- Division of Neuropathology, National Hospital for Neurology and Neurosurgery, University College London NHS Foundation Trust, London, UK.
- Department of Neurodegenerative Disease, Queen Square Institute of Neurology, University College London, London, UK.
- Division of Pediatric Glioma Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
ORCID-Profile: Sebastian Brandner, Sybren L N Maas
Förderung
- Medical Research Council
- Deutsche Krebshilfe
- Gemeinnützige Hertie‐Stiftung
Zitieren
APA
Hielscher, T., Sill, M., Sievers, P., Stichel, D., Brandner, S., Jones, D. T. W., von Deimling, A., Sahm, F., & Maas, S. L. N. (2023). Clinical implementation of integrated molecular‐morphologic risk prediction for meningioma. Brain Pathology, 33(3). https://doi.org/10.1111/bpa.13132
Vancouver
Hielscher T, Sill M, Sievers P, Stichel D, Brandner S, Jones DTW, et al. Clinical implementation of integrated molecular‐morphologic risk prediction for meningioma. Brain Pathology. 2023;33(3). doi:10.1111/bpa.13132
BibTeX
@article{Hielscher2023,
author = {Hielscher, Thomas and Sill, Martin and Sievers, Philipp and Stichel, Damian and Brandner, Sebastian and Jones, David T W and von Deimling, Andreas and Sahm, Felix and Maas, Sybren L N},
title = {Clinical implementation of integrated molecular‐morphologic risk prediction for meningioma},
journal = {Brain Pathology},
year = {2023},
volume = {33},
number = {3},
doi = {10.1111/bpa.13132}
}
EUVIMED